Synmosa Biopharma Corporation (TPEX:4114)

Taiwan · Delayed Price · Currency is TWD

30.30

+0.15 (0.50%)

Oct 16, 2026, 1:30 PM CST

Market Cap	16.40B -3.4%
Revenue (ttm)	6.68B +11.4%
Net Income	827.17M +14.0%
EPS	1.53 +8.6%
Shares Out	541.12M
PE Ratio	19.83
Forward PE	n/a
Dividend	0.79 (2.60%)
Ex-Dividend Date	Jul 17, 2026

Volume	1,632,609
Open	30.20
Previous Close	30.15
Day's Range	30.15 - 30.45
52-Week Range	27.55 - 32.41
Beta	-0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale r... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1959

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 4114

Full Company Profile

Financial Performance

In 2025, Synmosa Biopharma's revenue was 6.19 billion, an increase of 11.53% compared to the previous year's 5.55 billion. Earnings were 821.85 million, an increase of 20.03%.

Financial Statements